Opinion: The FDA just broke the logjam on interchangeable biologics. Here’s what that decision means
The Food and Drug Administration’s decision on Wednesday to approve a long-acting insulin called Semglee (insulin glargine-yfgn) as the first interchangeable biologic licensed for the U.S. market represents a major …
Read More